Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

New York's Booming Biopharma Job Market: A Hub for Life Sciences Talent

New York's life sciences sector is experiencing significant growth, with thousands of job opportunities emerging across the state. Recent data from the Partnership Fund for New York City reveals that the Empire State is home to 3,610 life sciences businesses as of December 31, 2024. This flourishing ecosystem has added nearly 17,000 jobs over the past decade, with accelerated employment growth observed in New York City since 2019.

NoahAI News10/31/2025

Gilead Advances HIV Treatment Pipeline with New Lenacapavir Combination

Gilead Sciences has made significant strides in its HIV treatment pipeline, announcing key developments during its recent third-quarter earnings call. The pharmaceutical giant is focusing on creating low-frequency treatment options, with lenacapavir at the forefront of these efforts.

NoahAI News10/31/2025

Boehringer Ingelheim Secures €640M Deal with Kyowa Kirin for Autoimmune Disease Program

Boehringer Ingelheim, the German pharmaceutical giant, has announced a significant collaboration with Japanese company Kyowa Kirin, marking another step in its pursuit of innovative autoimmune disease treatments. The deal, valued at up to €640 million ($743 million), centers on a preclinical small molecule program with potential applications in inflammatory conditions.

NoahAI News10/31/2025

Roche Secures $1B Biobucks Deal for Respiratory Disease Bispecific Antibody from Qyuns Therapeutics

In a significant move to bolster its respiratory disease pipeline, Swiss pharmaceutical giant Roche has inked a licensing agreement with Chinese biotech firm Qyuns Therapeutics. The deal, potentially worth over $1 billion, centers on QX031N, a clinical-stage bispecific antibody targeting both human thymic stromal lymphopoietin (TSLP) and human interleukin-33 (IL-33).

NoahAI News10/31/2025

Pharmaceutical Industry Update: Pipeline Cuts, Clinical Wins, and Strategic Deals

Takeda Pharmaceuticals has announced significant changes to its drug development pipeline, discontinuing several programs following strategic reviews and clinical setbacks. The Japanese pharmaceutical giant has halted development of TAK-341/MEDI1341, an alpha-synuclein antibody partnered with AstraZeneca, after a phase 2 failure in multiple system atrophy. Additionally, Takeda ceased work on danavorexton (TAK-925), an orexin-2 receptor agonist, for narcolepsy due to strategic considerations, though development for respiratory conditions continues.

NoahAI News10/31/2025

Leadership Shakeups and Controversial Departures Rock Pharmaceutical Industry

In a week of significant leadership changes across the pharmaceutical sector, several high-profile executives have stepped down or been ousted from their positions, while others have taken on new roles in key organizations. These shifts come amid ongoing debates over vaccine efficacy and sales practices, signaling potential changes in direction for affected companies and government agencies.

NoahAI News10/31/2025

Eli Lilly Discontinues P2X7 Inhibitor for Pain, Reshaping Pipeline Strategy

Eli Lilly, a leading pharmaceutical company, has announced the discontinuation of its phase 2 P2X7 inhibitor, LY3857210, for pain indications. This decision marks another significant pivot in the company's pain pipeline, following recent adjustments earlier this year.

NoahAI News10/31/2025

GSK Expands COPD Portfolio with $745M Deal for Empirico's Oligonucleotide Asset

GSK has announced a significant expansion of its chronic obstructive pulmonary disease (COPD) pipeline, signing a deal worth up to $745 million with San Diego-based biotech Empirico for the rights to EMP-012, a siRNA oligonucleotide currently in phase 1 trials. This move underscores GSK's commitment to advancing novel treatments for inflammatory respiratory diseases and strengthens its position in the oligonucleotide therapeutics space.

NoahAI News10/28/2025

Lonza Acquires Rapid Microbial Testing Firm Redberry SAS to Enhance Quality Control Capabilities

Swiss contract development and manufacturing organization (CDMO) Lonza has announced its acquisition of French rapid microbiology testing firm Redberry SAS, in a move aimed at strengthening and accelerating quality control testing processes. The acquisition, revealed on October 27, 2025, is set to address the pharmaceutical industry's growing demand for faster product releases without compromising safety or regulatory standards.

NoahAI News10/28/2025

BioMarin to Divest Hemophilia Gene Therapy Roctavian Amid Slow Sales

BioMarin Pharmaceutical has announced plans to divest Roctavian, its gene therapy for hemophilia A, following nearly three years of disappointing sales performance. The decision marks a significant shift for a product once hailed as a potential blockbuster in the pharmaceutical industry.

NoahAI News10/28/2025

BridgeBio's Muscular Dystrophy Drug Shows Promise in Late-Stage Trial

BridgeBio Pharma has announced promising interim results from a Phase III trial of its oral small molecule BBP-418, designed to treat limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The positive data puts the company on track to file for FDA approval in the first half of 2026, potentially offering hope in an indication that currently lacks a disease-modifying treatment.

NoahAI News10/28/2025

Intellia Halts Phase III CRISPR Trials Due to Severe Liver Toxicity

Intellia Therapeutics has announced a temporary pause in its Phase III clinical trials for nexiguran ziclumeran (nex-z), a CRISPR-based gene therapy targeting transthyretin amyloidosis (ATTR), following a life-threatening adverse event in a patient. The decision has sent shockwaves through the biotech industry, raising concerns about the safety of CRISPR-based therapies and their potential impact on liver function.

NoahAI News10/28/2025

«1...4 5 6...67 »